torical series, suggesting either patient selection or an effect of the "intermediate"-dose CBP. Importantly, fewer relapses have occurred in the high-dose arm, but survival in the two arms is similar, presumably because of the early toxic mortality of 7.4%.
The Scandinavian trial compared three cycles of induction FEC followed by one high-dose cycle of CTCb with nine cycles of moderately high dose "tailored" FEC. (That is, the doses in mg/m 2 of FEC were tailored to individual tolerance up to 600 of 5-fluorouracil, 120 of epirubicin, and 1800 of cyclophosphamide per cycle.) The cumulative doses for tailored therapy that were actually delivered substantially exceeded those for the CTCb arm. Therefore, this study assesses the role of one high-dose cycle compared with nine cycles of chemotherapy intensified to individual tolerance with a higher cumulative chemotherapy dose. The study probably includes some patients with metastatic disease, since patients with involved marrow and abnormal bone scans were included (5).
At a median follow-up of just 3 years, disease-free survival is significantly improved for the six cycles of tailored-dose therapy compared with one high-dose cycle. Of the 251 patients on the tailored-dose arm, six developed leukemia and three developed myelodysplasia, compared with none on the marrow transplant arm. Because the median follow-up is only 3 years, additional cases are possible or even likely. Topoisomerase-associated leukemias tend to occur early, but alkylating agent-associated leukemias would emerge later than the current median follow-up. Stem cells collected after three cycles of chemotherapy for use in stem cell support may be less damaged than those exposed in situ to nine chemotherapy cycles escalated to patient tolerance.
The South African study was reported to be a direct comparison of conventional CAF versus two cycles of high-dose chemotherapy (without a preceding induction phase) (2). An independent audit team documented many inconsistencies in eligibility criteria, as well as in reported data. Documentation of treatment and outcome for the control group was totally unavailable. The title of the protocol provided to the audit team, however, suggests that the control group was treated with cyclophosphamide, mitoxantrone, and vincristine and not CAF. On the basis of these findings, the abstract has been withdrawn and the data are best considered unreliable (6).
The Netherlands Cancer Institute randomly assigned 81 women with an involved apical axillary lymph node after four initial courses of FEC either to an additional cycle of FEC or to CTCb with stem cell support followed by surgery, radiation therapy, and tamoxifen for 2 years. At a median follow-up of 49 months, DSF and overall survival were similar. Although this randomized phase II study is mature, in that most of the expected events have already occurred, this small study cannot exclude differences of less than 30% in survival (7). Thus, the Dutch undertook their larger study, described above, which currently shows about a 15% advantage in DFS for high-dose therapy in the group with the longest follow-up.
A second small study at The University of Texas M. D. Anderson Cancer Center, Houston, randomly assigned 78 patients to eight cycles of FAC with or without two cycles of high-dose chemotherapy with cyclophosphamide, etoposide, and cisplatin. Three patients randomly assigned to conventional-dose therapy received transplants elsewhere; six patients randomly assigned to receive a transplant did not receive it. With a median follow-up exceeding 78 months, no advantage for high-dose chemotherapy has emerged. This study was closed because of slow accrual, but it has the statistical power to rule out differences in outcome of more than 30% (8).
Ongoing or unpublished randomized high-dose therapy studies in breast cancer are shown in Table 2 .
SUMMARY OF RANDOMIZED ADJUVANT TRIALS
On the basis of the data so far, mortality is 0%-2% in all studies but one-about the same as for conventional dose therapy. The South African adjuvant study has been discredited. The Scandinavian study, which compares one high-dose cycle with six cycles of escalated dose tailored to individual tolerance, does not compare conventional-with high-dose chemotherapy. Two small studies, comparing standard FAC or FEC with or without high-dose chemotherapy, report no differences but can not exclude a 30% difference. In fact, one was the pilot study for the larger Netherlands trial, which currently has a trend in favor of high-dose therapy, with statistically significant differences in DFS and overall survival in the first 285 patients accrued with 6 years of follow-up. These two Dutch studies provide an object lesson in biostatistics: specifically, the issue of drawing conclusions from underpowered studies. The U.S. study, comparing high-dose therapy with an intermediate-dose therapy, has a statistically significant decreased relapse rate for the high-dose arm-a biological effect similar to that in the Dutch study. However, the higher mortality obviates any advantage of the highdose therapy.
Survival curves for conventional adjuvant therapy of breast cancer show no plateau indicating cure for 15-20 years after diagnosis (9). Additional follow-up of the two larger randomized trials that compare high-dose with relatively conventional-dose chemotherapy and the completion of other ongoing randomized trials will provide more reliable information to determine what role high-dose chemotherapy regimens should have, if any, in the management of high-risk primary breast cancer.
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